Skip to main content

Vicore Pharma Holding

Vicore Pharma Holding AB is a Swedish clinical-stage biopharmaceutical company focused on the development of innovative treatments for rare lung diseases and severe fibrotic conditions. The company utilizes its proprietary competence in angiotensin receptor type two (AT2) agonism to advance therapeutic candidates, such as C21, designed to stimulate tissue repair and inhibit fibrosis in diseases like idiopathic pulmonary fibrosis and pulmonary hypertension. Its core operations encompass preclinical drug research, biomarker tracking, and clinical trial development. As a clinical-stage biopharmaceutical firm, the company generates minimal commercial revenue and finances its research through capital market offerings and strategic collaborations. Vicore Pharma holds a specialized position in rare respiratory disease drug discovery. The company is headquartered in Gothenburg, Sweden, and its shares trade on Nasdaq Stockholm.

5 of the funds FundTelligence covers report a position in Vicore Pharma Holding.

Legal name
Vicore Pharma Holding AB
Sector
Health Care
Country
Sweden
Funds holding it
5

Funds holding Vicore Pharma Holding

Loading...